Pulse Biosciences Q2 FY26 net loss widens to $24.66 million; revenue swings to $434,000

Reuters2026/08/06 20:35

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Pulse Biosciences posted Q2 GAAP net loss of USD 24.7 million, widening from USD 19.2 million a year earlier; GAAP loss per share widened to USD 0.36.
Revenue was USD 434,000, versus no revenue a year earlier, as it stayed in a controlled commercial launch focused on market development.
GAAP costs and expenses rose to USD 25.7 million from USD 20.3 million, driven by higher clinical-program investment and compensation-related spend.
Cash and cash equivalents climbed to USD 101.6 million at June 30 from USD 68.3 million at March 31, following USD 46.8 million net ATM proceeds.
NANOPULSE-AF enrollment topped 82 evaluable patients, with completion targeted for early Q4; the company is progressing toward a 2H 2026 CE Mark submission.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulse Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608061605BIZWIRE_USPR_____20260806_BW008388) on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Pulse Biosciences Q2 FY26 net loss widens to $24.66 million; revenue swings to $434,000

You may also like

Crypto prices